These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 36483225)

  • 21. A clinical case of severe disease burden: an erythrodermic psoriatic patient treated with secukinumab.
    Galluzzo M; D'Adamio S; Campione E; Mazzilli S; Bianchi L; Talamonti M
    J Dermatolog Treat; 2018 Sep; ():1-11. PubMed ID: 30256706
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Guselkumab, a human interleukin-23 monoclonal antibody in Japanese patients with generalized pustular psoriasis and erythrodermic psoriasis: Efficacy and safety analyses of a 52-week, phase 3, multicenter, open-label study.
    Sano S; Kubo H; Morishima H; Goto R; Zheng R; Nakagawa H
    J Dermatol; 2018 May; 45(5):529-539. PubMed ID: 29569397
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials.
    Reich K; Papp KA; Blauvelt A; Tyring SK; Sinclair R; Thaçi D; Nograles K; Mehta A; Cichanowitz N; Li Q; Liu K; La Rosa C; Green S; Kimball AB
    Lancet; 2017 Jul; 390(10091):276-288. PubMed ID: 28596043
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of tildrakizumab in Japanese patients with moderate to severe plaque psoriasis: Results from a 64-week phase 3 study (reSURFACE 1).
    Igarashi A; Nakagawa H; Morita A; Okubo Y; Sano S; Imafuku S; Tada Y; Honma M; Mendelsohn AM; Kawamura M; Ohtsuki M
    J Dermatol; 2021 Jun; 48(6):853-863. PubMed ID: 33630387
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ixekizumab Improved Refractory Erythrodermic Psoriasis with Comorbid Diffuse Alopecia: A Case Report with 52-Week Follow-Up.
    Song B; Liu X; Jin H
    Clin Cosmet Investig Dermatol; 2024; 17():1811-1814. PubMed ID: 39139845
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Multifaceted Analysis of IL-23A- and/or EBI3-Including Cytokines Produced by Psoriatic Keratinocytes.
    Tachibana K; Tang N; Urakami H; Kajita A; Kobashi M; Nomura H; Sasakura M; Sugihara S; Jiang F; Tomonobu N; Sakaguchi M; Ouchida M; Morizane S
    Int J Mol Sci; 2021 Nov; 22(23):. PubMed ID: 34884474
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Real-world practice indirect comparison between guselkumab, risankizumab, and tildrakizumab: results from an Italian 28-week retrospective study.
    Megna M; Tommasino N; Potestio L; Battista T; Ruggiero A; Noto M; Fabbrocini G; Genco L
    J Dermatolog Treat; 2022 Sep; 33(6):2813-2820. PubMed ID: 35603992
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tildrakizumab for the treatment of psoriasis.
    Sinclair R; Thirthar Palanivelu V
    Expert Rev Clin Immunol; 2019 Jan; 15(1):5-12. PubMed ID: 30394141
    [No Abstract]   [Full Text] [Related]  

  • 29. The potential utility of tildrakizumab: an interleukin-23 inhibitor for the treatment of psoriasis.
    Yiu ZZ; Warren RB
    Expert Opin Investig Drugs; 2017 Feb; 26(2):243-249. PubMed ID: 28042732
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tildrakizumab for treatment of moderate to severe psoriasis: an expert opinion of efficacy, safety, and use in special populations.
    Galluzzo M; Chiricozzi A; Cinotti E; Brunasso G; Congedo M; Esposito M; Franchi C; Malara G; Narcisi A; Piaserico S; Tiberio R; Argenziano G; Fabbrocini G; Parodi A
    Expert Opin Biol Ther; 2022 Mar; 22(3):367-376. PubMed ID: 34607513
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Erythrodermic psoriasis in post-coronavirus disease 2019 patient.
    Batubara IS; Budianti WK
    Asia Pac Allergy; 2022 Apr; 12(2):e16. PubMed ID: 35571549
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tildrakizumab in the treatment of psoriasis - literature review.
    Banaszczyk K
    Reumatologia; 2019; 57(4):234-238. PubMed ID: 31548750
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nonclinical safety of tildrakizumab, a humanized anti-IL-23p19 monoclonal antibody, in nonhuman primates.
    Santostefano M; Herzyk D; Montgomery D; Wolf J
    Regul Toxicol Pharmacol; 2019 Nov; 108():104476. PubMed ID: 31536773
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sustained and continuously improved efficacy of tildrakizumab in patients with moderate-to-severe plaque psoriasis.
    Elewski B; Menter A; Crowley J; Tyring S; Zhao Y; Lowry S; Rozzo S; Mendelsohn AM; Parno J; Gordon K
    J Dermatolog Treat; 2020 Dec; 31(8):763-768. PubMed ID: 31268369
    [No Abstract]   [Full Text] [Related]  

  • 35. Safety of tildrakizumab for moderate-to-severe plaque psoriasis: pooled analysis of three randomized controlled trials.
    Blauvelt A; Reich K; Papp KA; Kimball AB; Gooderham M; Tyring SK; Sinclair R; Thaçi D; Li Q; Cichanowitz N; Green S; La Rosa C
    Br J Dermatol; 2018 Sep; 179(3):615-622. PubMed ID: 29742274
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tildrakizumab: First Global Approval.
    Markham A
    Drugs; 2018 Jun; 78(8):845-849. PubMed ID: 29752706
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Systematic Literature Review and Bucher Indirect Comparison: Tildrakizumab versus Guselkumab.
    Du Jardin KG; Hurtado Lopez P; Lange M; McCool R; Maeso Naval S; Quickert S
    J Health Econ Outcomes Res; 2020; 7(2):123-129. PubMed ID: 32766377
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Two cases of Erythrodermic psoriasis treated with Golimumab.
    Kudsi M; Alzabibi MA; Shibani M
    Ann Med Surg (Lond); 2022 Jun; 78():103961. PubMed ID: 35734731
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetics of Tildrakizumab (MK-3222), an Anti-IL-23 Monoclonal Antibody, After Intravenous or Subcutaneous Administration in Healthy Subjects.
    Khalilieh S; Hodsman P; Xu C; Tzontcheva A; Glasgow S; Montgomery D
    Basic Clin Pharmacol Toxicol; 2018 Sep; 123(3):294-300. PubMed ID: 29510001
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.